Par launches authorized generic version of AstraZeneca heart drug

Share this article:
Par Pharmaceuticals said it began shipping an authorized generic version of AstraZeneca beta blocker Toprol-XL. The announcement followed the launch of a 25-mg generic version of metoprolol in the US by Eon Labs, part of Sandoz. Par’s authorized generic also is being distributed in a 25-mg dosage, a size which accounts for about 20% of Toprol-XL US sales, AZ said. Toprol-XL had $838.9 million in sales during the first six months of 2006 and $1.49 billion in sales in 2005, according to IMS Health. An extended-release pill whose patent expires in September 2007, Toprol-XL’s patent was deemed invalid earlier this year in litigation involving KV Pharmaceutical, Andrx Pharmaceuticals, Andrx Corp. and Eon Labs Manufacturing. AZ appealed that decision and, notwithstanding its deal with Par, said it will continue to sell branded Toprol-XL in the US.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.